Main content

    Multiple Sclerosis Clinical Trials

    Sutter Health participates in clinical trials related to Multiple Sclerosis throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients.
    Description: The primary purpose of this study is to determine which baseline and yearly response factors predict the clinical disease-free status response in subsequent years. The study will also clarify the effectiveness of Tysabri at establishing and maintaining this overall disease-free state.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients age 18 to 45 with a diagnosis of Relapsing Multiple Sclerosis who test negative for the Anti-JCV antibody and are treatment-naïve to disease-modifying therapy and approved to use Tysabri.
    Status: Active and closed to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis (ORATORIO)
    Description: The purpose of this research is to investigate the efficacy of ocrelizumab compared with placebo in patients with primary progressive multiple sclerosis.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients with Primary Progressive Multiple Sclerosis.
    Status: Active and closed to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, RN, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: A Phase II, Multicenter, Unblinded Study to Evaluate the Long-term Safety and Efficacy of Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) (OCRE EXT)
    Description: The purpose of this research is to test the efficacy and safety of ocrelizumab, the humanized version of the anti-CD20 antigen monoclonal antibody Rituximab, in patients with relapsing-remitting multiple sclerosis.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients with Relapsing Remitting Multiple Sclerosis.
    Status: Active and closed to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, RN, 510-204-1757
    Email: CassonL@sutterhealth.org

    Title: Plegridy™ (peginterferon β-1a) Real World Effectiveness and Safety Observational Program (POP)
    Description: The purpose of this observational study is to find out more about the long-term safety and effectiveness of Plegridy, which has been approved by the FDA, over approximately a five year time period.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients 18 and older with RMS who has been newly prescribed Plegridy (or who participated in Study 105MS302 or Study 105MS303) and who is willing and able to complete PROs with minimal assistance
    Location: Alta Bates Summit Medical Center
    Contact: Lucinda Casson, RN, 510-204-1757
    Email: CassonL@sutterhealth.org

    > See All Neurology Clinical Trials by Condition